Medicine Information

Brinzopt

Name: Brinzopt
Brand: Brinzopt
Rating: 4.5 (117 reviews)

Ophthalmic Suspension1% (10 mg/mL)Antiglaucoma preparations, Carbonic anhydrase inhibitorsATC: S01EC04

Generic Name

brinzopt-1-suspension

Manufacturer

Alcon (Innovator)

Country

USA

Loading images...

Price Details

Current market pricing information

Variant	Unit Price	Strip Price
brinzopt 1 suspension	৳ 550.00	N/A

Description

Overview of the medicine

Brinzopt 1% Suspension contains Brinzolamide, which is an ophthalmic carbonic anhydrase inhibitor used to lower elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It works by reducing the production of fluid inside the eye.

Uses & Indications

To lower elevated intraocular pressure in patients with ocular hypertension.

To lower elevated intraocular pressure in patients with open-angle glaucoma.

Dosage

Adults

One drop in the affected eye(s) three times daily. Shake well before use.

Elderly

No specific dosage adjustment is required for elderly patients.

Renal_impairment

Brinzolamide has not been studied in patients with severe renal impairment (creatinine clearance < 30 mL/min). It is not recommended in such patients.

How to Take

For ophthalmic use only. Shake the bottle well before each use. Instill one drop into the conjunctival sac of the affected eye(s). Avoid touching the dropper tip to the eye or any other surface to prevent contamination. If more than one topical ophthalmic drug is being used, they should be administered at least 5 minutes apart.

Mechanism of Action

Brinzolamide inhibits carbonic anhydrase in the ciliary body of the eye. This inhibition reduces the formation of bicarbonate ions, which in turn reduces the secretion of aqueous humor, leading to a decrease in intraocular pressure.

Pharmacokinetics

Onset

Intraocular pressure reduction usually observed within 2 hours.

Excretion

Excreted predominantly in the urine as unchanged drug and its N-desethyl metabolite.

Half life

The apparent elimination half-life from red blood cells is approximately 111 days.

Absorption

Systemic absorption occurs after ocular administration, but it's generally low. Peak blood concentrations of brinzolamide and its metabolite are low.

Metabolism

Primarily metabolized in the liver by N-dealkylation to N-desethyl brinzolamide, which is also a carbonic anhydrase inhibitor.

Side Effects

Contraindications

Hypersensitivity to the active substance, other sulfonamides, or to any of the excipients.
Patients with severe renal impairment (creatinine clearance < 30 mL/min).
Patients with hyperchloraemic acidosis.

Drug Interactions

High-dose Salicylates

Caution is advised due to the potential for systemic acidosis.

Oral Carbonic Anhydrase Inhibitors

Potential for additive systemic effects, so concomitant use is not recommended.

Storage

Store at 2°C to 25°C (36°F to 77°F). Protect from light. Do not freeze. Keep the bottle tightly closed when not in use. Keep out of reach of children.

Overdose

Ocular overdose is unlikely to cause systemic toxicity due to low systemic absorption. If accidentally ingested, symptoms may include electrolyte imbalance, acidosis, and central nervous system effects. Treatment should be symptomatic and supportive.

Pregnancy & Lactation

Pregnancy: Use only if the potential benefit justifies the potential risk to the fetus. Lactation: It is not known whether brinzolamide is excreted in human milk. A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Frequently Asked Questions

Common questions about this medicine

Pack Sizes

5 mL ophthalmic suspension

Shelf Life

Unopened: 24-36 months. After opening: Discard 28 days after first opening.

Availability

Pharmacies, Hospitals

Approval Status

FDA Approved (as Brinzolamide)

Patent Status

Generic available

Clinical Trials

Brinzolamide 1% Ophthalmic Suspension has been extensively studied in clinical trials for its efficacy and safety in reducing intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Studies have shown significant IOP reduction compared to placebo.

Lab Monitoring

No specific routine lab monitoring is required for ophthalmic use. However, if there are concerns about systemic absorption (e.g., in patients with severe renal impairment), monitoring of serum electrolytes (especially potassium) may be considered.

Doctor Notes

Regularly monitor intraocular pressure (IOP) and assess optic nerve head for progression.
Advise patients on proper instillation technique to maximize efficacy and minimize contamination.
Be mindful of potential systemic absorption and interactions, especially with other carbonic anhydrase inhibitors or high-dose salicylates.

Patient Guidelines

Shake the bottle well before each use.
Remove contact lenses before applying eye drops and wait at least 15 minutes before reinserting them.
Avoid touching the dropper tip to your eye or any other surface to prevent contamination.
If you are using other eye drops, wait at least 5 minutes between each application.

Missed Dose Advice

If you miss a dose, apply it as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not apply a double dose to make up for a missed one.

Driving Precautions

Brinzopt 1% Suspension may cause temporary blurred vision or other visual disturbances which could affect the ability to drive or operate machinery. Patients should be advised not to drive or operate machinery until their vision clears.

Lifestyle Advice

Regularly attend your scheduled eye check-ups to monitor your intraocular pressure and overall eye health.
Maintain a healthy lifestyle, including a balanced diet and regular exercise, as advised by your doctor.